Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib, PD-1 Antibody, and Chemotherapy in Advanced Gastric Cancer
NCT05025033Phase 2Completed
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started May 2019; status: completed.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05025033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05025033.